$79,146,088

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

biotechactiveONGOING · MOD OF 2020 CONTRACT

WORK BEGAN2020-09-28·LATEST ACTION2026-04-02·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50120C00177_7505_-NONE-_-NONE-

Award description

TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS.

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Develop medical countermeasures to treat antibiotic-resistant bacterial infections.

Sub-sectors

medical-countermeasuresantibiotic-resistancemcm-development

Why this matters

Antibiotic resistance is a critical public health threat; MCMs are essential for pandemic preparedness and biodefense.

Supply-chain signal

Signals demand for specialized biotech manufacturing, clinical trial infrastructure, and regulatory pathway support for novel therapeutics.

U.S.–China competition angle

U.S. biodefense investment to maintain leadership in MCM development against emerging resistant pathogens of concern.

Generated by award_classification v2.0.0 via claude-haiku-4-5-20251001 on 2026-05-15. Cost: $0.002157.

Period of performance

Start

2020-09-28

End

2027-01-31

Status

activein 258 days

Recipient

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75A50120C00177_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.